Clinical Trial Update: Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of Conivaptan (YM087) in patients with acute decompensated heart failure has completed. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Decompensated Heart Failure
• Heart Failure

Drugs mentioned

• Conivaptan (conivaptan)

Snippet

Sponsor: Cumberland Pharmaceuticals | Conditions: Chronic Heart Failure | Phase 2 | Status: COMPLETED